Nabla
PrivateLast Round
Series C
Jun 17, 2025
Est. Valuation
$180M
Total Funding Raised
$114.3M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Nabla is a healthcare technology company that develops an AI-powered ambient clinical documentation platform designed to automate clinical notes and streamline administrative workflows for healthcare providers.
Sector
Healthcare & Life Sciences
Verticals
EHR & EMR, Medical AI, NLP & Conversational AI, Vertical SaaS, Revenue Cycle
Business Model
B2B
Customer Profile
Subscription SaaS, Usage-Based SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nabla Comparables
Compare Nabla with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| DeepScribe | 91% | |
| HBox | 87% | |
| Abridge Inc | 87% | |
Nabla Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 17, 2025 | ||||
| Series B | Jan 5, 2024 | ||||
| Early Funding | Apr 7, 2021 |
Key People
Founding team and executive leadership
Nabla Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cathay Capital | Series C |
| HV Capital | Series C |
| DST Global | Series C |
| Firstminute Capital | Early Funding |
| Build Collective | Series C |
| Artemis | Early Funding |
| Build Collective | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 10, 2026
Dr. Matt Sakumoto appointed as Chief Clinical Product Officer.
- Feb 8, 2026
Added Aultman Medical Group, an enterprise healthcare company, as a customer.
Nabla Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Nabla's valuation, stock price, and market status.